Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. - Wikidata - awgldk - TriplyDB

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

http://www.wikidata.org/entity/Q40070060

about

Inhibition of autophagy by TAB2 and TAB3 Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition Chloroquine and hydroxychloroquine for cancer therapy Signal transduction inhibitors in treatment of myelodysplastic syndromes Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch: Proteasomal inhibitors for anticancer therapy Trial watch: Cardiac glycosides and cancer therapy Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells Differentiation therapy of leukemia: 3 decades of development.Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.Proteomic and genetic approaches identify Syk as an AML target.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Trial Watch: Toll-like receptor agonists in oncological indications.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.Survivin selectively modulates genes deregulated in human leukemia stem cells.Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia Trial Watch: Monoclonal antibodies in cancer therapy Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Independent transcriptional reprogramming and apoptosis induction by cisplatin.Erlotinib antagonizes ABC transporters in acute myeloid leukemia.Epidermal growth factor regulates hematopoietic regeneration after radiation injury Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia Genomic approaches to small molecule discovery.EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens.Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts Is there a role for differentiating therapy in non-APL AML?Emerging biological therapies for the treatment of myelodysplastic syndromes.Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.Identification of new possible targets for leukemia treatment by kinase activity profiling.

P2860

Q24297091-3EFF895F-F6FD-4A26-A318-0E090A50671A Q24606978-95B8758F-9004-4CA8-9176-FF4D8D0B1575 Q26827797-90AF01E8-45C7-479C-9B36-C68E109C2E52 Q26829903-40EC061E-399E-4009-A5E2-3E41B2A87BA3 Q26993238-45E8820F-F482-4C9F-BC9E-82F1859C5B47 Q27021951-490ED931-610F-41DC-9A3A-B81B7F030FE7 Q28082910-3CAB86EC-2C70-4B51-8013-704FEB2A9C4C Q28395830-C2F0E35D-D78C-4F4E-9E78-627B9D3812F2 Q28548235-17C2C4DF-547F-4C18-8AEB-106CE911189A Q33409795-388AD323-EF4E-4716-B81A-CC270B48B30C Q33414866-F53F804C-2D76-421A-9D69-E60AF60F9354 Q33577098-25035A13-3B39-49F6-A4D1-2F6B1985EF49 Q33775647-2B4E45D2-D299-4338-B31D-90AFE55D9254 Q33878578-6C956101-E7F4-4A49-8015-66464C5AC6A8 Q34081881-3806239E-5F1A-4517-B10E-4047CFC0D219 Q34117127-3C05A864-815C-495B-84BB-21BD3022D856 Q34205052-0A57397F-45D5-47E6-9CC2-F9E33BF55340 Q34495409-867BB4B6-96BC-4364-B415-19ED3BD85FCD Q34628707-7FCA2756-2972-4CD9-B2E0-E3C755EDEA2F Q35093305-6192EA60-A4E4-4B77-BFC4-D2D39E8DE339 Q36038408-BEDD6A2C-2A76-4516-96E1-05C6E80284FB Q36194849-D22CE625-C261-459A-98F6-0326D5607F6A Q36304190-0FD4CCC1-9AC4-43F2-A279-EFE27349BA78 Q36426524-C3D00FC6-678E-444F-8B7D-08144806D5B1 Q36674536-BE67F3E6-B5BB-411C-9D27-892212C43033 Q36882696-E07AA086-69DB-490F-9AFB-A07C54EC5337 Q37104233-ADD66349-B8EC-48D6-BE68-B3034F347C2D Q37123272-960F844C-369D-42DE-A05E-184F4942051A Q37406963-E8F0F07D-749A-43C3-B707-8568BEE3D169 Q37420045-F9BCA31D-892A-409B-A6B1-4FE471AAC90E Q37680934-C6E8A4F5-AEE6-4DF1-A4C3-D5A0488D8413 Q37694901-A9BDBCE2-09CF-417E-A6BB-3FC072124AEF Q37705923-28C84A6C-7A5D-4882-9597-A191BE52D980 Q37815790-7E7E9D49-436A-4C8D-9097-2B6286C139F9 Q38834981-7ECB0F37-5034-414A-A9EB-42B71F70648F Q39255686-37AAE098-3E60-43BF-A9CE-64B0EB24DE5C Q39335663-557DFE61-69E5-4AB1-B590-173724864B7B Q39413114-371E63D7-9F74-4467-9756-F2BFD07A81B0 Q39439229-6E19044E-8D05-487C-B422-36C89270CC72 Q39623499-A186CB60-9B86-40F9-BEE0-BAC1E34B9E3C

P2860

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

http://www.wikidata.org/entity/Q40070060

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

@en

type

label

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

@en

prefLabel

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

@en

P1433

Q40070060-5DBF69FE-FD11-46E4-ABAD-D422F5F4782D

P1476

Q40070060-44BA3018-046A-4163-A495-8FD25AF4FF91

P2093

Q40070060-0CC291CF-4436-482C-977D-F67D93F4407E

Q40070060-1BA4FA29-8D35-488B-B1DA-F3E6A669EAD3

Q40070060-5D5FA8C3-74C4-4E5E-9BC9-551BC72B94B0

Q40070060-6A8215D8-4FD3-45FE-B9F5-228884BBEB3B

Q40070060-A1EF3854-81CE-4F7A-B7EC-22C67F1EEE5A

Q40070060-B1EABAF0-C939-4FFE-87B3-7944C6C41B64

Q40070060-C2983739-3A6B-48DB-905F-1B4B8485860C

Q40070060-DCB9E96C-E672-4106-BE0F-CF203698498D

P304

Q40070060-EC915CAA-CF0F-462E-98E2-B6CEA9D307FB

P31

Q40070060-59CE8906-3BCE-4632-B415-DCE539E079C6

P356

Q40070060-1037B0C7-A445-4063-8C5F-DACFC6210179

P407

Q40070060-2362F2B9-669B-416F-B7E2-0D1EB610E8E8

P433

Q40070060-B8FDC2B4-CA17-446F-98B2-9BEA22437A87

P478

Q40070060-CB638D2D-F55F-4D2F-BD21-349BA635C6DC

P50

Q40070060-08AF23A2-9960-4A89-8464-50AB4DDEFAF2

Q40070060-396BDDAB-653B-4493-BA7C-CA866813851B

Q40070060-8709E6EE-2FFA-4E0E-94D3-541483AEDA29

Q40070060-99829B15-7A09-4A14-A684-AC3A546052FA

P577

Q40070060-67B8459A-5FF9-4D0D-9D8D-3B3AB8B46372

P5875

Q40070060-BBAC6E52-0678-47D0-BCEF-9DDECF92E161

P698

Q40070060-4F1A2287-1D77-4172-BB5F-B84EE97935BE

P356

BLOOD-2007-07-100362

P1433

P1476

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

@en

P2093

Antoine Martin

http://www.w3.org/2001/XMLSchema#string

Claire Fabre

http://www.w3.org/2001/XMLSchema#string

Claude Gardin

http://www.w3.org/2001/XMLSchema#string

Génèviève Le Roux

http://www.w3.org/2001/XMLSchema#string

Jennifer Grosjean

http://www.w3.org/2001/XMLSchema#string

Lionel Adès

http://www.w3.org/2001/XMLSchema#string

Simone Boehrer

http://www.w3.org/2001/XMLSchema#string

Thorsten Braun

http://www.w3.org/2001/XMLSchema#string

P304

2170-2180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-07-100362

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Galluzzi

Stéphane de Botton

P577

2007-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5920534

http://www.w3.org/2001/XMLSchema#string

P698

17925489

http://www.w3.org/2001/XMLSchema#string